COMMUNIQUÉS West-GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2025 Financial Results
29/10/2025
Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54 [...]
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
29/10/2025
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and [...]
STERIS Announces Dividend of $0.63 per share
29/10/2025
DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
29/10/2025
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various [...]
Vaxil Announces Non-Brokered Private Placement
29/10/2025
Not for distribution by US newswire or in United States NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), is pleased to announce that the Company [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
29/10/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
29/10/2025
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and [...]
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
29/10/2025
Châtillon, France, 29 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « [...]
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
29/10/2025
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Curia publie son rapport ESG (environnement, social et gouvernance) 2024
29/10/2025
ALBANY, New York, 29 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la publication de [...]
CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
29/10/2025
NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
29/10/2025
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma [...]
EmblemHealth and Prime Therapeutics Pioneer New Pharmacy Benefit Collaboration
29/10/2025
Unique partnership, in collaboration with Amazon Pharmacy and Judi Health, brings transparent pricing, digital convenience, and fast, free home delivery of prescription medications for members NEW YORK, Oct. 29, 2025 ( [...]
RAMSAY SANTE : communiqué de mise à disposition du document d'enregistrement universel 2025
29/10/2025
COMMUNIQUÉ DE PRESSE Paris, le 29 octobre 2025 COMMUNIQUÉ DE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2025 Le Document d’enregistrement universel 2025 de Ramsay Générale de Santé a été déposé auprès de [...]
RAMSAY SANTE : availability of the Universal Registration Document 2025
29/10/2025
PRESS RELEASE Paris, 29 th October 2025 AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT 2025 Ramsay Générale de Santé's 2025 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) [...]
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/10/2025
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
29/10/2025
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKs [...]

Pages